# A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab

> **NCT07543731** · — · NOT_YET_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 5995 (estimated)

## Conditions studied

- Cardiovascular Diseases
- Atherosclerotic Cardiovascular Disease
- Hypercholesterolemia, Familial

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07543731
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-21
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 5995 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07543731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07543731, "A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07543731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*